The global Acute Migraine Drugs market was worth USD 8.40 billion in 2021 and is anticipated to expand at a CAGR of 7.82% between 2023 and 2028. The rising prevalence of migraine among the working population, as well as increasing healthcare expenditure, are driving up demand for acute migraine medications.
Triptans are widely used migraine medications because they are selective serotonin receptor agonists. They work by increasing serotonin levels in the brain, which reduces inflammation and constricts blood vessels, thereby ending the headache or migraine. Triptans account for approximately 46% of the overall market share by drug type segment in 2021. For Mild pain treatment of Migraine, over-the-counter medications such as Naproxen, Ibuprofen, Aspirin, Acetaminophen, Pseudoephedrine, or phenylephrine are widely utilized.
With patients’ suffering from migraine and the limitations of triptan, there are significant opportunities in the treatment of acute migraine. In this scenario, there are a number of novel therapeutic options that include Ubrelvy, Reyvow and Nurtec ODT. However, one of the treatments making huge inroads is Impel's Trudhesa, which is a self-administered drug device for the intranasal delivery of DHE. Trudhesa was approved by the FDA in September 2021.
Women account for about three-quarters of all migraine cases. Women aged 20 to 45 are the most prone to suffer from migraines. Moreover, hormonal variations in women may be a migraine trigger, and menstrual migraines affect around 60% of female migraineurs. The Americas accounted for a major share of the market in terms of value in 2021 and the region is expected to keep retaining the largest share of the overall sales of acute migraine drugs.
Triptans are widely used migraine medications because they are selective serotonin receptor agonists. They work by increasing serotonin levels in the brain, which reduces inflammation and constricts blood vessels, thereby ending the headache or migraine. Triptans account for approximately 46% of the overall market share by drug type segment in 2021. For Mild pain treatment of Migraine, over-the-counter medications such as Naproxen, Ibuprofen, Aspirin, Acetaminophen, Pseudoephedrine, or phenylephrine are widely utilized.
With patients’ suffering from migraine and the limitations of triptan, there are significant opportunities in the treatment of acute migraine. In this scenario, there are a number of novel therapeutic options that include Ubrelvy, Reyvow and Nurtec ODT. However, one of the treatments making huge inroads is Impel's Trudhesa, which is a self-administered drug device for the intranasal delivery of DHE. Trudhesa was approved by the FDA in September 2021.
Women account for about three-quarters of all migraine cases. Women aged 20 to 45 are the most prone to suffer from migraines. Moreover, hormonal variations in women may be a migraine trigger, and menstrual migraines affect around 60% of female migraineurs. The Americas accounted for a major share of the market in terms of value in 2021 and the region is expected to keep retaining the largest share of the overall sales of acute migraine drugs.
Scope of the Report
- The report analyses the Acute Migraine Drugs Market by Value (USD Billion).
- The report presents the analysis of Acute Migraine Drugs market for the historical period of 2018-2021, the base year 2022 and the forecast period of 2023-2028.
- The report analyses the Acute Migraine Drugs Market by Drug Type (Ergot Alkaloids, Analgesics, Triptans, Fragrance, Other Drug Types)
- The report analyses the Acute Migraine Drugs Market By Route of Administration (Intravenous, Oral, Nasal, Other Routes of Administration)
- The report analyses the Acute Migraine Drugs Market By Availability (Over The Counter, Prescription)
- The Global Acute Migraine Drugs Market has been analysed by countries (United States, Canada, Germany, UK, France, Italy, Spain, China, Japan, India).
- The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By Drug type and Availability.
- Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
- The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies profiled in the report include, Eli Lilly and Company, GSK plc., Bayer AG, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Novartis, Merck & Co., Inc., Pfizer Inc., Boehringer Ingelheim.
Key Target Audience:
- Healthcare and Pharmaceutical Companies
- Chronic Migraine Patients
- Episodic migraine Patients
- Leading Acute Migraine Drugs Brands
- Research & Development Organizations
Table of Contents
1. Market Background1.1 Scope and Product Outlook
1.2 Executive Summary
1.3 Research Methodology
2. Strategic Recommendations
3. Global Acute Migraine Drugs Market: Historic and Forecast (2018-2028 )
3.1 Impact Analysis of Macro Economic Factors on Acute Migraine Drugs Market
3.2 Global Acute Migraine Drugs Market: Ecosystem Analysis
3.2.1 Migraine: fact sheet
3.2.2 Migraine - Nurtec ODT and Ubrelvy patient’s Therapy abandonment data
3.2.3 Pipeline scenario of Acute Migraine Drugs
3.2.4 Annual Sales of Triptans and Non Triptans in U.S
3.3 Global Acute Migraine Drugs Market: Dashboard
3.4 Global Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
3.5 Impact of COVID-19 on Acute Migraine Drugs Market
3.6 Global Acute Migraine Drugs Market Segmentation: By Drug Type
3.6.1 Global Acute Migraine Drugs Market, By Drug Type Overview
3.6.2 Global Acute Migraine Drugs Market Size, By Ergot Alkaloids, By Value, 2018H-2028F (USD Billion & CAGR)
3.6.3 Global Acute Migraine Drugs Market Size, By Analgesics, By Value, 2018H-2028F (USD Billion & CAGR)
3.6.4 Global Acute Migraine Drugs Market Size, By Triptans, By Value, 2018H-2028F (USD Billion & CAGR)
3.6.5 Global Acute Migraine Drugs Market Size, By Other Drug Types, By Value, 2018H-2028F (USD Billion & CAGR)
3.7 Global Acute Migraine Drugs Market Segmentation: By Route of Administration
3.7.1 Global Acute Migraine Drugs Market, By Route of Administration Overview
3.7.2 Global Acute Migraine Drugs Market Size, By Intravenous, By Value, 2018H-2028F (USD Billion & CAGR)
3.7.3 Global Acute Migraine Drugs Market Size, By Oral, By Value, 2018H-2028F (USD Billion & CAGR)
3.7.4 Global Acute Migraine Drugs Market Size, By Nasal, By Value, 2018H-2028F (USD Billion & CAGR)
3.7.5 Global Acute Migraine Drugs Market Size, By Other Routes of Administration, By Value, 2018H-2028F (USD Billion & CAGR)
3.8 Global Acute Migraine Drugs Market Segmentation: By Availability
3.8.1 Global Acute Migraine Drugs Market, By Availability Overview
3.8.2 Global Acute Migraine Drugs Market Size, By Over The Counter, By Value, 2018H-2028F (USD Billion & CAGR)
3.8.3 Global Acute Migraine Drugs Market Size, By Prescription, By Value, 2018H-2028F (USD Billion & CAGR)
4. Global Acute Migraine Drugs Market, Regional Analysis
4.1 Regional Coverage of the Study
4.2 Regional Snapshot
5. Americas Acute Migraine Drugs Market: Historic and Forecast (2018-2028 )
5.1 Americas Acute Migraine Drugs Market: Snapshot
5.2 Americas Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
5.3 Americas Acute Migraine Drugs Market: Key Factors
5.4 Americas Acute Migraine Drugs Market Segmentation: By Drug Type
5.4.1 Americas Acute Migraine Drugs Market, By Drug Type Overview
5.4.2 Americas Acute Migraine Drugs Market Size, By Ergot Alkaloids, By Value, 2018H-2028F (USD Billion & CAGR)
5.4.3 Americas Acute Migraine Drugs Market Size, By Analgesics, By Value, 2018H-2028F (USD Billion & CAGR)
5.4.4 Americas Acute Migraine Drugs Market Size, By Triptans, By Value, 2018H-2028F (USD Billion & CAGR)
5.4.5 Americas Acute Migraine Drugs Market Size, By Other Drug Types, By Value, 2018H-2028F (USD Billion & CAGR)
5.5 Americas Acute Migraine Drugs Market Segmentation: By Route of Administration
5.5.1 Americas Acute Migraine Drugs Market, By Route of Administration Overview
5.5.2 Americas Acute Migraine Drugs Market Size, By Intravenous, By Value, 2018H-2028F (USD Billion & CAGR)
5.5.3 Americas Acute Migraine Drugs Market Size, By Oral, By Value, 2018H-2028F (USD Billion & CAGR)
5.5.4 Americas Acute Migraine Drugs Market Size, By Nasal, By Value, 2018H-2028F (USD Billion & CAGR)
5.5.5 Americas Acute Migraine Drugs Market Size, By Other Routes of Administration, By Value, 2018H-2028F (USD Billion & CAGR)
5.6 Americas Acute Migraine Drugs Market Segmentation: By Availability
5.6.1 Americas Acute Migraine Drugs Market, By Availability Overview
5.6.2 Americas Acute Migraine Drugs Market Size, By Over The Counter, By Value, 2018H-2028F (USD Billion & CAGR)
5.6.3 Americas Acute Migraine Drugs Market Size, By Prescription, By Value, 2018H-2028F (USD Billion & CAGR)
5.7 Americas Acute Migraine Drugs Market Segmentation: By Country
5.7.1 Americas Acute Migraine Drugs Market Segmentation, By Country Overview
5.7.2 United States Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
5.7.2.1 United States Acute Migraine Drugs Market, By Drug Type
5.7.2.2 United States Acute Migraine Drugs Market, By Route of Administration
5.7.2.3 United States Acute Migraine Drugs Market, By Availability
5.7.3 Canada Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
5.7.3.1 Canada Acute Migraine Drugs Market, By Drug Type
5.7.3.2 Canada Acute Migraine Drugs Market, By Route of Administration
5.7.3.3 Canada Acute Migraine Drugs Market, By Availability
5.7.4 Rest of Americas Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
5.7.4.1 Rest of Americas Acute Migraine Drugs Market, By Drug Type
5.7.4.2 Rest of Americas Acute Migraine Drugs Market, By Route of Administration
5.7.4.3 Rest of Americas Acute Migraine Drugs Market, By Availability
6. Europe Acute Migraine Drugs Market: Historic and Forecast (2018-2028 )
6.1 Europe Acute Migraine Drugs Market: Snapshot
6.2 Europe Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
6.3 Europe Acute Migraine Drugs Market: Key Factors
6.4 Europe Acute Migraine Drugs Market Segmentation: By Drug Type
6.4.1 Europe Acute Migraine Drugs Market, By Drug Type Overview
6.4.2 Europe Acute Migraine Drugs Market Size, By Ergot Alkaloids, By Value, 2018H-2028F (USD Billion & CAGR)
6.4.3 Europe Acute Migraine Drugs Market Size, By Analgesics, By Value, 2018H-2028F (USD Billion & CAGR)
6.4.4 Europe Acute Migraine Drugs Market Size, By Triptans, By Value, 2018H-2028F (USD Billion & CAGR)
6.4.5 Europe Acute Migraine Drugs Market Size, By Other Drug Types, By Value, 2018H-2028F (USD Billion & CAGR)
6.5 Europe Acute Migraine Drugs Market Segmentation: By Route of Administration
6.5.1 Europe Acute Migraine Drugs Market, By Route of Administration Overview
6.5.2 Europe Acute Migraine Drugs Market Size, By Intravenous, By Value, 2018H-2028F (USD Billion & CAGR)
6.5.3 Europe Acute Migraine Drugs Market Size, By Oral, By Value, 2018H-2028F (USD Billion & CAGR)
6.5.4 Europe Acute Migraine Drugs Market Size, By Nasal, By Value, 2018H-2028F (USD Billion & CAGR)
6.5.5 Europe Acute Migraine Drugs Market Size, By Other Routes of Administration, By Value, 2018H-2028F (USD Billion & CAGR)
6.6 Europe Acute Migraine Drugs Market Segmentation: By Availability
6.6.1 Europe Acute Migraine Drugs Market, By Availability Overview
6.6.2 Europe Acute Migraine Drugs Market Size, By Over The Counter, By Value, 2018H-2028F (USD Billion & CAGR)
6.6.3 Europe Acute Migraine Drugs Market Size, By Prescription, By Value, 2018H-2028F (USD Billion & CAGR)
6.7 Europe Acute Migraine Drugs Market Segmentation: By Country
6.7.1 Europe Acute Migraine Drugs Market Segmentation, By Country, Overview
6.7.2 Germany Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
6.7.2.1 Germany Acute Migraine Drugs Market, By Drug Type
6.7.2.2 Germany Acute Migraine Drugs Market, By Route of Administration
6.7.2.3 Germany Acute Migraine Drugs Market, By Availability
6.7.3 United Kingdom Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
6.7.3.1 United Kingdom Acute Migraine Drugs Market, By Drug Type
6.7.3.2 United Kingdom Acute Migraine Drugs Market, By Route of Administration
6.7.3.3 United Kingdom Acute Migraine Drugs Market, By Availability
6.7.4 France Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
6.7.4.1 France Acute Migraine Drugs Market, By Drug Type
6.7.4.2 France Acute Migraine Drugs Market, By Route of Administration
6.7.4.3 France Acute Migraine Drugs Market, By Availability
6.7.5 Italy Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
6.7.5.1 Italy Acute Migraine Drugs Market, By Drug Type
6.7.5.2 Italy Acute Migraine Drugs Market, By Route of Administration
6.7.5.3 Italy Acute Migraine Drugs Market, By Availability
6.7.6 Spain Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
6.7.6.1 Spain Acute Migraine Drugs Market, By Drug Type
6.7.6.2 Spain Acute Migraine Drugs Market, By Route of Administration
6.7.6.3 Spain Acute Migraine Drugs Market, By Availability
6.7.7 Rest of Europe Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
6.7.7.1 Rest of Europe Acute Migraine Drugs Market, By Drug Type
6.7.7.2 Rest of Europe Acute Migraine Drugs Market, By Route of Administration
6.7.7.3 Rest of Europe Acute Migraine Drugs Market, By Availability
7. Asia Pacific Acute Migraine Drugs Market: Historic and Forecast (2018-2028 )
7.1 Asia Pacific Acute Migraine Drugs Market: Snapshot
7.2 Asia Pacific Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
7.3 Asia Pacific Acute Migraine Drugs Market: Key Factors
7.4 Asia Pacific Acute Migraine Drugs Market Segmentation: By Drug Type
7.4.1 Asia Pacific Acute Migraine Drugs Market, By Drug Type Overview
7.4.2 Asia Pacific Acute Migraine Drugs Market Size, By Ergot Alkaloids, By Value, 2018H-2028F (USD Billion & CAGR)
7.4.3 Asia Pacific Acute Migraine Drugs Market Size, By Analgesics, By Value, 2018H-2028F (USD Billion & CAGR)
7.4.4 Asia Pacific Acute Migraine Drugs Market Size, By Triptans, By Value, 2018H-2028F (USD Billion & CAGR)
7.4.5 Asia Pacific Acute Migraine Drugs Market Size, By Other Drug Types, By Value, 2018H-2028F (USD Billion & CAGR)
7.5 Asia Pacific Acute Migraine Drugs Market Segmentation: By Route of Administration
7.5.1 Asia Pacific Acute Migraine Drugs Market, By Route of Administration Overview
7.5.2 Asia Pacific Acute Migraine Drugs Market Size, By Intravenous, By Value, 2018H-2028F (USD Billion & CAGR)
7.5.3 Asia Pacific Acute Migraine Drugs Market Size, By Oral, By Value, 2018H-2028F (USD Billion & CAGR)
7.5.4 Asia Pacific Acute Migraine Drugs Market Size, By Nasal, By Value, 2018H-2028F (USD Billion & CAGR)
7.5.5 Asia Pacific Acute Migraine Drugs Market Size, By Other Routes of Administration, By Value, 2018H-2028F (USD Billion & CAGR)
7.6 Asia Pacific Acute Migraine Drugs Market Segmentation: By Availability
7.6.1 Asia Pacific Acute Migraine Drugs Market, By Availability Overview
7.6.2 Asia Pacific Acute Migraine Drugs Market Size, By Over the Counter, By Value, 2018H-2028F (USD Billion & CAGR)
7.6.3 Asia Pacific Acute Migraine Drugs Market Size, By Prescription, By Value, 2018H-2028F (USD Billion & CAGR)
7.7 Asia Pacific Acute Migraine Drugs Market Segmentation: By Country
7.7.1 Asia Pacific Acute Migraine Drugs Market, By Country Overview
7.7.2 China Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
7.7.2.1 China Acute Migraine Drugs Market, By Drug Type
7.7.2.2 China Acute Migraine Drugs Market, By Route of Administration
7.7.2.3 China Acute Migraine Drugs Market, By Availability
7.7.3 Japan Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
7.7.3.1 Japan Acute Migraine Drugs Market, By Drug Type
7.7.3.2 Japan Acute Migraine Drugs Market, By Route of Administration
7.7.3.3 Japan Acute Migraine Drugs Market, By Availability
7.7.4 India Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
7.7.4.1 India Acute Migraine Drugs Market, By Drug Type
7.7.4.2 India Acute Migraine Drugs Market, By Route of Administration
7.7.4.3 India Acute Migraine Drugs Market, By Availability
7.7.5 Rest Of Asia Pacific Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
7.7.5.1 Rest of Asia Pacific Acute Migraine Drugs Market, By Drug Type
7.7.5.2 Rest Of Asia Pacific Acute Migraine Drugs Market, By Route of Administration
7.7.5.3 Rest Of Asia Pacific Acute Migraine Drugs Market, By Availability
8. Middle East & Africa Acute Migraine Drugs Market: Historic and Forecast (2018-2028 )
8.1 Middle East & Africa Acute Migraine Drugs Market: Snapshot
8.2 Middle East & Africa Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
8.3 Middle East & Africa Acute Migraine Drugs Market: Key Factors
8.4 Middle East & Africa Acute Migraine Drugs Market Segmentation: By Drug Type
8.4.1 Middle East & Africa Acute Migraine Drugs Market, By Drug Type Overview
8.4.2 Middle East & Africa Acute Migraine Drugs Market Size, By Ergot Alkaloids, By Value, 2018H-2028F (USD Billion & CAGR)
8.4.3 Middle East & Africa Acute Migraine Drugs Market Size, By Analgesics, By Value, 2018H-2028F (USD Billion & CAGR)
8.4.4 Middle East & Africa Acute Migraine Drugs Market Size, By Triptans, By Value, 2018H-2028F (USD Billion & CAGR)
8.4.5 Middle East & Africa Acute Migraine Drugs Market Size, By Other Drug Types, By Value, 2018H-2028F (USD Billion & CAGR)
8.5 Middle East & Africa Acute Migraine Drugs Market Segmentation: By Route of Administration
8.5.1 Middle East & Africa Acute Migraine Drugs Market, By Route of Administration Overview
8.5.1 Middle East & Africa Acute Migraine Drugs Market Size, By Intravenous, By Value, 2018H-2028F (USD Billion & CAGR)
8.5.1 Middle East & Africa Acute Migraine Drugs Market Size, By Oral, By Value, 2018H-2028F (USD Billion & CAGR)
8.5.1 Middle East & Africa Acute Migraine Drugs Market Size, By Nasal, By Value, 2018H-2028F (USD Billion & CAGR)
8.5.1 Middle East & Africa Acute Migraine Drugs Market Size, By Other Routes of Administration, By Value, 2018H-2028F (USD Billion & CAGR)
8.6 Middle East & Africa Acute Migraine Drugs Market Segmentation: By Availability
8.6.1 Middle East & Africa Acute Migraine Drugs Market, By Availability Overview
8.6.2 Middle East & Africa Acute Migraine Drugs Market Size, By Over the Counter, By Value, 2018H-2028F (USD Billion & CAGR)
8.6.3 Middle East & Africa Acute Migraine Drugs Market Size, By Prescription, By Value, 2018H-2028F (USD Billion & CAGR)
9. Market Dynamics
9.1 Impact assessment of Market Dynamics on Global Acute Migraine Drugs Market
9.2 Drivers
9.3 Restraints
9.4 Trends
10. Industry Ecosystem Analysis
10.1 Macro-Economic Factor Assessment
10.2 Value Chain Analysis
10.3 Porter’s Five Forces Model
11. Competitive Positioning
11.1 Companies’ Product Positioning
11.2 Market Position Matrix
11.3 Market Share Analysis of Acute Migraine Drugs Market
11.4 Company Profiles
11.4.1 Eli Lilly and Company
11.4.2 GSK plc.
11.4.3 Bayer AG
11.4.4 Johnson & Johnson
11.4.5 Teva Pharmaceutical Industries Ltd.
11.4.6 AbbVie Inc.
11.4.7 Novartis
11.4.8 Merck & Co., Inc.
11.4.9 Pfizer Inc.
11.4.10 Boehringer Ingelheim
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 260 |
| Published | February 2023 |
| Forecast Period | 2023 - 2028 |
| Estimated Market Value ( USD | $ 9.65 Billion |
| Forecasted Market Value ( USD | $ 14.06 Billion |
| Compound Annual Growth Rate | 7.8% |
| Regions Covered | Global |
